Precision BioSciences, Inc. (NASDAQ:DTIL) Insider J. Jefferson Smith Sells 10,287 Shares

Precision BioSciences, Inc. (NASDAQ:DTIL) insider J. Jefferson Smith sold 10,287 shares of the business’s stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $4.79, for a total value of $49,274.73. Following the sale, the insider now owns 87,440 shares of the company’s stock, valued at approximately $418,837.60. This represents a 10.53 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Precision BioSciences Stock Up 9.0 %

Shares of DTIL stock traded up $0.41 on Wednesday, hitting $4.97. The stock had a trading volume of 269,389 shares, compared to its average volume of 1,803,615. Precision BioSciences, Inc. has a 12-month low of $3.61 and a 12-month high of $19.43. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22. The business has a 50 day moving average of $5.62 and a 200 day moving average of $8.04. The stock has a market cap of $38.12 million, a price-to-earnings ratio of 82.85 and a beta of 1.51.

Hedge Funds Weigh In On Precision BioSciences

A hedge fund recently raised its stake in Precision BioSciences stock. Janus Henderson Group PLC increased its holdings in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 10.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 702,069 shares of the company’s stock after acquiring an additional 68,943 shares during the quarter. Janus Henderson Group PLC owned approximately 9.15% of Precision BioSciences worth $6,322,000 as of its most recent SEC filing. 37.99% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

DTIL has been the subject of a number of recent research reports. BMO Capital Markets upgraded shares of Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price target for the company in a research note on Friday, January 10th. HC Wainwright restated a “buy” rating and issued a $60.00 target price on shares of Precision BioSciences in a report on Friday, January 10th.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.